Search Results - Dent, R.

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

    Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer by Dent, R., Lindeman, G., Clemons, M., Wildiers, H., Chan, Arlene, McCarthy, N., Singer, C., Lowe, E., Watkins, C., Carmichael, J.

    Published 2013
    Get full text
  2. 2
    Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial

    Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvan... by Gianni, L., Mansutti, M., Anton, A., Calvo, L., Bisagni, G., Bermejo, B., Semiglazov, V., Thill, M., Chacon, J., Chan, Arlene, Morales, S., Alvarez, I., Plazaola, A., Zambetti, M., Redfern, A., Dittrich, C., Dent, R., Magazzu, D., De Fato, R., Valagussa, P., Tusquets, I.

    Published 2018
    Get full text

Search Tools: